Abciximab (genetical Recombination)

Abciximab (genetical Recombination) Uses, Dosage, Side Effects, Food Interaction and all others data.

Abciximab (genetical Recombination) is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab (genetical Recombination) binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

Abciximab (genetical Recombination) inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. A single intravenous bolus dose from 0.15 mg/kg to 0.30 mg/kg produced rapid dose-dependent inhibition of platelet function. After two hours post-injection with a dose of 0.25 - 0.30 mg/kg, 80% of the GPIIb/IIIa receptors were blocked and platelet aggregation was prevented. GPIIb/IIIa is the major surface receptor involved in the final pathway of platelet aggregation. Bleeding time increases to over 30 minutes at the aforementioned doses. To compare, baseline values were five minutes.

Abciximab (genetical Recombination)
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Abciximab (genetical Recombination)
Availability	Prescription only
Generic	Abciximab
Abciximab Other Names	Abciximab, Abciximab (genetical recombination), c7E3
Related Drugs	ReoPro
Type
Formula	C₆₄₆₂H₉₉₆₄N₁₆₉₀O₂₀₄₉S₄₈
Weight	145651.1 Da
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Abciximab (genetical Recombination) is a monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.

Abciximab (genetical Recombination) is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab (genetical Recombination) is intended for use with aspirin and heparin and has been studied only in that setting.

Abciximab (genetical Recombination) is also used to associated treatment for these conditions: Thrombotic events

How Abciximab (genetical Recombination) works

Abciximab (genetical Recombination) binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPIIb/IIIa. By binding to the vitronectin receptor (also known as the αvβ3 integrin), abciximab blocks effects mediated by this integrin which include cell adhesion. Furthermore, abciximab blocks Mac-1 receptor on monocytes and neutrophils thus inhibiting monocyte adhesion.

Food Interaction

Avoid herbs and supplements with anticoagulant/antiplatelet activity. Additive antiplatelet activity may increase the risk of bleeding. Examples include ginseng, ginkgo, ginger, and garlic.

Abciximab (genetical Recombination) Hypertension interaction

[Major] The use of gp11b<111a platelet inhibitors is contraindicated in patients with active internal bleeding, recent significant gastrointestinal or genitourinary bleeding (within 6 weeks), recent trauma or major surgery (within 6 weeks), history of bleeding diathesis, recent stroke (within 4 weeks), history of hemorrhage stroke or residual neurologic deficit, intracranial defect (aneurysm, arteriovenous malformation, neoplasm), uncontrolled hypertension (SBP > 180; DBP > 110), or thrombocytopenia (

Abciximab (genetical Recombination) Drug Interaction

Major: heparin, heparin, clopidogrel, clopidogrelModerate: aspirin, aspirinUnknown: charcoal, charcoal, spironolactone, spironolactone, glucose, glucose, fentanyl, fentanyl, sodium iodide, sodium iodide, arginine, arginine, acetaminophen, acetaminophen

Abciximab (genetical Recombination) Disease Interaction

Major: bleeding risks

Half Life

Following intravenous bolus administration, free plasma concentrations of Abciximab (genetical Recombination) decrease rapidly with an initial half-life of less than 10 minutes and a second phase half-life of about 30 minutes, probably related to rapid binding to the platelet GPIIb/IIIa receptors.